Inavir meets flu prevention endpoint in Phase III
This article was originally published in Scrip
Executive Summary
Australian firm Biota reports that a Phase III prevention study of Inavir (laninamivir octanoate, CS-8958), conducted by Daiichi Sankyo, met its primary endpoint by significantly reducing the transmission of influenza within a household. Daiichi Sankyo intends to apply for approval to market Inavir for the prevention of influenza by the end of the year.